SecBot SecBot

TBPH drug pipeline

Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bearish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 3 (failed)
Time to marketNot applicable. The drug failed all Phase 3 trials and development has been terminated.

ampreloxetine Updated Nov 9

What to watch

Ampreloxetine is a failed drug with no active development program. Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) in a deal that closed September 2026, and TBPH shares were delisted. There are no upcoming catalysts for this drug. For investors, the relevant surviving public company is Zymeworks (ZYME), which acquired Theravance primarily for its commercial YUPELRI respiratory asset, not for ampreloxetine.

Bull case
  • The drug had Orphan Drug Designation from the FDA for nOH in MSA patients, reflecting an unmet medical need.
  • Theravance continued to present new analyses at medical conferences even after the initial Phase 3 failures, suggesting some investigators saw signals worth exploring.
  • The acquisition by Zymeworks at $17/share provided a floor for TBPH shareholders after the CYPRESS failure sent the stock lower.
Bear case
  • Ampreloxetine failed all three Phase 3 trials it entered (SEQUOIA in 2021, REDWOOD in 2022, CYPRESS in March 2026), none meeting their primary endpoints.
  • The CYPRESS failure in MSA patients triggered a 50% workforce reduction and the end of Theravance's internal R&D, making further development of ampreloxetine highly unlikely.
  • Theravance Biopharma was acquired by Zymeworks and delisted from Nasdaq on September 24, 2026. TBPH shares no longer trade publicly.

Other drugs in filings and trials

no drug report yet

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
TD-1211A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)Phase 2Completed95May 2012
TD-1211A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced ConstipationPhase 2Completed69May 2012
TD-1211A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced ConstipationPhase 2Completed217May 2012
TD-1211A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced ConstipationPhase 2Completed102Oct 2010